Tag: Justin Madders

The below Parliamentary question was asked by Justin Madders on 2016-10-18.

To ask the Secretary of State for Health, what representations he has received from the Chief Executive of NHS England on the financial settlement allocated for the NHS for (a) 2017-18, (b) 2018-19 and (c) 2019-20.

Mr Philip Dunne

The Spending Review settled the level of funding that the National Health Service in England will receive over the course of this Parliament, with the NHS England Chief Executive a full party to the discussions with HM Treasury. As the Chief Executive said at the time the Spending Review was announced, “our case for the NHS has been heard and actively supported’’. Regular discussions around the finances of the NHS continue to take place between my Rt. hon. Friend the Secretary of State and the Chief Executive of NHS England.

The NHS will be receiving £10 billion more per year in real terms by 2020-21 compared to 2014-15. The following table sets out the financial settlement allocated to the NHS.

NHS budget for Spending Review period

Revenue and capital combined	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21
Total (£ million)	100,500	105,975	109,337	111,824	114,929	119,035
Real terms increase on previous year (%)		3.7%	1.3%	0.3%	0.7%	1.3%
Real terms increase on 2015-16 baseline (£ billion)		3.8	5.3	5.8	6.7	8.4
Real terms increase on 2014-15 baseline (£ billion)	2.0	6.0	7.0	8.0	9.0	10.0

Note:

These figures differ from the NHS Total Departmental Expenditure Limit (TDEL) figures announced at the Spending Review due to a number of technical adjustments, including transfers of functions. The main transfer of function is the move of 0-5 public health services from NHS England to local government. There are a small number of other transfers including the move of the Leadership Academy to Health Education England. To ensure comparability of numbers, in this table £500 million has been removed from the 2015-16 baseline, representing 6 months of funding for 0-5 public health services between 1 April and 30 September 2015 and these other planned transfers.

The below Parliamentary question was asked by Justin Madders on 2015-11-16.

To ask the Secretary of State for Transport, with reference to section 32(1) of the Pilotage Act 1987, what plans he has to bring forward legislative proposals to maintain pilotage standards in areas where harbour authorities now have the power to impose compulsory pilotage upon shipping.

Mr Robert Goodwill

None. The Pilotage Act 1987 already requires Competent Harbour Authorities to keep under consideration what pilotage services need to be provided to secure the safety of ships navigating their waters, including the circumstances in which pilotage should be compulsory, and to provide such pilotage services accordingly.

The below Parliamentary question was asked by Justin Madders on 2015-12-03.

To ask the Secretary of State for Health, pursuant to his oral contribution of 30 November 2015, Official Report, column 33, on the estimated number of patients who may have had a vital operation cancelled, how many patients who had such an operation cancelled had it rescheduled to a time within 24 hours of the original scheduled operation.

Ben Gummer

On 30 November, based on information provided by hospital trusts, NHS England estimated that around 3,000 procedures that were due to take place on 1 December 2015 were planned to be rescheduled. It has not collected information or estimated how many of these could not be rebooked for 1 December 2015 once the proposed industrial action was suspended. There has been no estimate of how many vital procedures that were cancelled were rescheduled within 24 hours. These are operational matters for hospital trusts.

The below Parliamentary question was asked by Justin Madders on 2016-01-25.

To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of the Access to Medical Treatments (Innovation) Bill on reducing the length of time it takes to bring a new drug to market.

George Freeman

The purpose of the Access to Medical Treatments (Innovation) Bill is to promote access to innovative medical treatments. It is not specifically designed to reduce the length of time it takes to bring a new drug to market. To which end work is being done in parallel, notably through the Accelerated Access Review, which explores options to speed up access to innovative drugs, devices and diagnostics for National Health Service patients. Sir Hugh Taylor, the independent chair of the review will make his recommendations in the spring.

The below Parliamentary question was asked by Justin Madders on 2016-02-02.

To ask the Secretary of State for Health, what assessment he made of the potential merits of expanding the monitoring of healthcare-associated infections.

Ben Gummer

Public Health England undertakes monitoring of healthcare associated infections, which includes the mandatory healthcare associated infections surveillance system. These arrangements are regularly reviewed and changes introduced in 2015 include enhanced surveillance for very antibiotic resistant infections (carbapenemase-producing Enterobacteriaceae).

The below Parliamentary question was asked by Justin Madders on 2016-03-01.

To ask the Secretary of State for Health, how many UK citizens have a European Health Insurance Card (EHIC); and how many such people have used their EHIC to obtain state provided healthcare in other EU countries in each of the last five years.

Alistair Burt

The United Kingdom European Health Insurance Card (EHIC) means that people living in the UK are able to travel to the European Economic Area (EEA) safe in the knowledge that they will be able to receive free or reduced cost healthcare should they need it.

There are currently 27,570,911 cards in circulation, as of January 2016. The number of cards granted since 2006, providing such cover is:

2014/15 – 5,414,977

2013/14 – 5,571,060

2012/13 – 5,240,608

2011/12 – 6,830,734

2010/11 – 5,703,895

2009/10 – 4,162,170

2008/09 – 4,269,023

2007/08 – 4,160,935

2006/07 – 5,163,121

Source: Business Services Authority

The Department does not hold information about on how many people have used their UK EHIC to obtain state provided healthcare in another EEA country in any 12 month period. This is because data on UK EHIC usage is recorded by individual treatment episode rather than the card holder.

The below Parliamentary question was asked by Justin Madders on 2016-03-07.

To ask the Secretary of State for Health, how his Department plans to increase the understanding and use of social value in the design of healthcare services.

Alistair Burt

The Department is reviewing its work with the voluntary, community and social enterprise sector and will consider how to enhance the understanding and use of the Public Services (Social Value) Act 2012 as part of this work. The Department also intends to develop guidance for procurers and non-procurers on how to make best use of the Act. In addition, the Sustainable Development Unit, funded by NHS England and Public Health England, has established a programme of work on social value which includes providing guidance to commissioners and embedding social value in the Sustainability and Transformation Planning process underway across the health and care system.

The below Parliamentary question was asked by Justin Madders on 2016-04-13.

To ask the Secretary of State for Health, if he will make it his policy to adopt a target encouraging the reclassification of medicines from (a) prescription only medicine to pharmacy medicine status, (b) pharmacy medicine to general sales list medicine status and (c) prescription only medicine to general sales list medicine status; and if he will make a statement.

George Freeman

The Government is committed to the continued reclassification of medicines from prescription only to pharmacy classification and from pharmacy to general sales list classification when it is safe to do so and there is a clear benefit to public health. This is an important part of empowering patients to manage their own care. The Government’s medicines regulator, the Medicines and Healthcare products Regulatory Agency, is at the forefront of moves to reclassify medicines to non-prescription and is recognised as a leader in Europe in this regard.

Over the years reclassification has been facilitated by improving the regulatory environment for manufacturers to achieve successful reclassification of their products. Amendments to legislation were introduced in 2002 to reduce the legislative burden for reclassification; new guidance was published in 2012 to streamline the process; and in 2015 a United Kingdom platform was set up to maximise stakeholder engagement with the aim of encouraging further reclassification of medicines.

Patient safety remains the prime consideration in any decision to make a medicine available without prescription.

We are unable to calculate the total difference in cost to the public purse following these medicine reclassifications.

The attached tables contain the information for each of the last 25 years on medicines reclassified from prescription only medicine (POM) to Pharmacy (P) medicine and P medicine to general sales list (GSL) medicine. There are no examples of medicines which have been reclassified from POM to GSL. Where relevant, brand names have been included in brackets.

The lists represent the first reclassification either from POM to P or P to GSL of the product and further extensions such as wider indications, additional pack sizes or higher strengths have not been included.

Not all products listed are currently available, for various reasons, including both commercial and regulatory.

The below Parliamentary question was asked by Justin Madders on 2016-04-21.

To ask the Secretary of State for Health, how many formal complaints were made against NHS111 providers in each month since that service was launched.

Jane Ellison

This information is not held centrally.

The below Parliamentary question was asked by Justin Madders on 2016-05-24.

To ask the Secretary of State for Health, how many NHS trusts and foundation trusts met the 10 seven-day services clinical standards and the four priority standards set out by Sir Bruce Keogh in his December 2013 report, NHS Services, Seven Days a Week Forum: Summary of Initial Findings, in 2015-16.

Ben Gummer

There is a phased approach to implementation of the four priority standards. By March 2017, 25% of the population will be guaranteed access to the four standards, seven days a week, rising to the whole country by 2020.

An initial self-assessment of progress on meeting the four priority clinical standards was carried out by trusts in August 2015. This showed that around half of trusts are meeting two or more of the clinical standards. Following feedback from trusts, the self-assessment process is being improved for future surveys.